Laboratory Medicine Program

Phospholipase A2 Receptor Antibodies
(anti-PLA2R)

Clinical Decription:
Primary membranous nephropathy is an immune-mediated kidney disease. In up to 75% of patients with this disease, autoantibodies against M-type phospholipase A2 receptor (PLA2R) can be detected in serum. These autoantibodies are directly involved in formation of immune complexes that damage the glomerular basement membrane thus causing proteinuria. Serum Anti-PLA2R antibodies have high specificity for primary membranous nephropathy, and are hence utilized as a biomarker for differential diagnosis. Moreover, their baseline levels and direction for change over time, correlate, with immunologic activity and are used to guide treatment decisions. Clinical significance of anti-PLA2R values between 2-14 RU/ml is not well established. This test should not be used as a stand-alone test but an adjunct to other clinical information.
<br/><em>Anti PLA2R ELISA (IgG) test instruction-package insert EUROIMMUN analyzer 1 Manual. Bobart et al "Noninvasive diagnosis of primary membranous nephropathy using phospholipase A@ receptor antibodies. "Kidney international 95, no. 2 (2019): 429-438</em>

Method: ELISA; EUROIMMUN

Component Tests Used: n/a

Reference Ranges Used:
Negative:< 14 RU/mL; Borderline:= 14-19 RU/ml; Positive:>= 19 RU/ml

Specimen Type: Serum
Volume: n/a

Shipping: Refrigerated 2-8C (send on ice or freeze packs)

Special Instructions: n/a

Testing Schedule(s): Please call

Turnaround Time: 10 Business days

Download order form

For more information, call 416.340.5227 or 1.866.865.5227

Back to Search